J&J applies to U.S. FDA for STELARA® (ustekinumab) in pediatric ulcerative colitis

 

Expanded STELARA^® indication seeks to treat children two years of age and older with moderately to severely active ulcerative colitis, based on Week 52 data from UNIFI Jr

https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-u-s-fda-for-stelara-ustekinumab-in-the-treatment-of-pediatric-ulcerative-colitis